IMS 2022 | Key findings of the LocoMMotion study
Maria-Victoria Mateos
• 25 Aug 2022
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares some insights into the LocoMMotion study (NCT04035226), which is evaluating treatment options for patients with relapsed/refractory (R/R) multiple myeloma who have been previously exposed to a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody (mAb). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
